Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer (NCT07181161)
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Research Site — Fayetteville, Arkansas
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (52 Sites)
Showing the first 25 of 52 sites.
- Research Site — Fayetteville, Arkansas
- Research Site — Los Angeles, California
- Research Site — Towson, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Ann Arbor, Michigan
- Research Site — Detroit, Michigan
- Research Site — Buffalo, New York
- Research Site — New York, New York
- Research Site — Providence, Rhode Island
- Research Site — Myrtle Beach, South Carolina
- Research Site — Houston, Texas
- Research Site — Barretos,
- Research Site — Porto Alegre,
- Research Site — São Paulo,
- Research Site — Changsha,
- Research Site — Chengdu,
- Research Site — Wuhan,
- Research Site — Lyon,
- Research Site — Montpellier,
- Research Site — Saint-Herblain,
- Research Site — Suresnes,
- Research Site — Villejuif,
- Research Site — Milan,
- Research Site — Milan,
- Research Site — Milan,
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.